Figure 1.
![Figure 1. Kaplan-Meier survival curves. (A) RAEB patients (N = 336). (B) RAEB patients (N = 336) stratified by type of HMA used (azacitidine [AZA], N = 266 vs decitabine [DEC], N = 70). (C) RAEB patients (N = 336) stratified by those receiving ≥6 cycles (N = 159) or <6 cycles (N = 177) of the HMA.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/131/7/10.1182_blood-2017-10-811729/4/blood811729f1.jpeg?Expires=1724247059&Signature=hg7sFkxt2Nz-SR4hTnDU9dwVmJkzqET5g5STDJ9XA9FJ4DW478iXWdpkWtjhFWw0wnnwxqGF9lwho-IppGmpgrlHyyF5z6IldNfRX2Ga5zKPbJW3i5tBmUtR9aigC7NudQalrHzucioEb-HR4-k8hiT4ZEMJJ0Ge2oMqS142NN7jwXVc1PD0saPtn8K8ADS2wubpG-RDk-DmU37f~4SrPR~WM748w08TzkwE5xh7wWvmPDPPa0IgRD1Vz00X9WTD3lAlNC06lLfAjnVTKpYIA7OxQbl685ge1ZaC98BASh9lpNS6ehyWh48uLDiItb21NTZR0zcxWdG6qqr3XJEN3w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Kaplan-Meier survival curves. (A) RAEB patients (N = 336). (B) RAEB patients (N = 336) stratified by type of HMA used (azacitidine [AZA], N = 266 vs decitabine [DEC], N = 70). (C) RAEB patients (N = 336) stratified by those receiving ≥6 cycles (N = 159) or <6 cycles (N = 177) of the HMA.
